A Plus Biotechnology Co., Ltd.
A Plus Biotechnology Co., Ltd. engages in the manufacturing and wholesale of orthopedic and other medical devices. The company offers products for chest, shoulder, spine, elbow, wrist and hand, pelvic and hip, knee, foot and ankle, osteotomy, pediatric and ESF, biologics. It also provides technical support services and labor services. A Plus Biotechnology Co., Ltd. is based in New Taipei City, Ta… Read more
A Plus Biotechnology Co., Ltd. (6918) - Total Liabilities
Latest total liabilities as of September 2025: NT$273.98 Million TWD
Based on the latest financial reports, A Plus Biotechnology Co., Ltd. (6918) has total liabilities worth NT$273.98 Million TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
A Plus Biotechnology Co., Ltd. - Total Liabilities Trend (2021–2024)
This chart illustrates how A Plus Biotechnology Co., Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
A Plus Biotechnology Co., Ltd. Competitors by Total Liabilities
The table below lists competitors of A Plus Biotechnology Co., Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Taliworks Corporation Bhd
KLSE:8524
|
Malaysia | RM700.99 Million |
|
Mobiltel Iletisim Hizmetleri Sanayi ve Ticaret AS
IS:MOBTL
|
Turkey | TL3.83 Billion |
|
Altisource Portfolio Solutions SA
NASDAQ:ASPS
|
USA | $249.26 Million |
|
Bilendi
PA:ALBLD
|
France | €100.55 Million |
|
Flat Capital AB Series B
ST:FLAT-B
|
Sweden | Skr2.12 Million |
|
Insas Bhd
KLSE:3379
|
Malaysia | RM572.12 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down A Plus Biotechnology Co., Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how A Plus Biotechnology Co., Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for A Plus Biotechnology Co., Ltd. (2021–2024)
The table below shows the annual total liabilities of A Plus Biotechnology Co., Ltd. from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$258.27 Million | +6.12% |
| 2023-12-31 | NT$243.38 Million | -17.97% |
| 2022-12-31 | NT$296.71 Million | -18.02% |
| 2021-12-31 | NT$361.91 Million | -- |